Oritavancin

ApprovedSmall molecule

Oritavancin is one of 47 small molecule programs targeting Staphylococcus aureus infection. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Staphylococcus Aureus InfectionActive, not recruiting

Opioid Use DisorderActive, not recruiting

Staphylococcus Aureus InfectionApproved

Active, not recruiting

Opioid Use DisorderApproved

Active, not recruiting

Competition

Competitive Landscape

116 competitors in Opioid Use Disorder

#DrugCompanyPhaseTrials

Revia

Teva

Phase 3

2 2

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

4 3

Epidiolex

Jazz Pharmaceuticals

Phase 2

5 4

Dayvigo

Eisai

Phase 2

2 5

Mounjaro

Eli Lilly

Phase 2

1 6

Ozempic

Novo Nordisk

Phase 2

1 7

Vraylar

AbbVie

Phase 2

1 8

Victoza

Novo Nordisk

Phase 2

1 9

Diamox

Teva

Phase 2

—10

Buprenorphine/naloxone

Astellas

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tics2 trials

Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects

Completed·MMelinta Therapeutics, Inc.·Phase 1·NCT02470702·14 enrolled

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers

Completed· Novartis logo

Novartis·Phase 1·NCT02471690·56 enrolled

Intravenous2 trials

Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection

Completed· Novartis logo

Novartis·Phase 4·NCT02925416·22 enrolled

A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Completed· Novartis logo

Novartis·Phase 4·NCT02452918·17 enrolled

Opioid Use Disorder1 trial

Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use

Terminated·UUniversity of Maryland, Baltimore·Phase 4·NCT05521880·2 enrolled

Infections1 trial

A Study for Patients With Complicated Skin and Skin Structure Infections

Completed·TTarganta Therapeutics Corporation·Phase 2·NCT00514527·294 enrolled

Observational Study1 trial

A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting

Completed·MMelinta Therapeutics, Inc.··NCT03159403·325 enrolled

3 more indications

Staphylococcus aureus infection1 trial

Oritavancin for Staphylococcus Aureus Infections in Opioid Users

Withdrawn·UUniversity of Pennsylvania·Phase 4·NCT03761953

Coagulation1 trial

Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers

Completed·MMelinta Therapeutics, Inc.·Phase 1·NCT02357524·20 enrolled

Bacterial Infections1 trial

Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections

Completed·MMelinta Therapeutics, Inc.·Phase 1·NCT02134301·41 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Oritavancin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oritavancin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oritavancin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Melinta Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMelinta Therapeutics, Inc.

Oritavancin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tics2 trials

Intravenous2 trials

Opioid Use Disorder1 trial

Infections1 trial

Observational Study1 trial

Staphylococcus aureus infection1 trial

Coagulation1 trial

Bacterial Infections1 trial

References

Drug Info

Quick Facts

Related News